PharmiWeb9h
IMFINZI® (durvalumab) approved in the US as first…
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
PharmiWeb14h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...